The United States Food and Drug Administration (FDA) has granted approval to market SecreFlo (synthetic porcine secretin), the first synthetic version of the hormone secretin. SecreFlo has been approved for stimulation of pancreatic secretions, including bicarbonate, to aid in the diagnosis of pancreatic exocrine dysfunction, or chronic pancreatitis and stimulation of gastrin secretion to aid in the diagnosis of gastrinoma, a pancreatic tumor which may become cancerous.

"We are pleased that the FDA has approved SecreFlo," stated Walter C. Herlihy, president and CEO of Repligen. "We look forward to providing this important diagnostic tool to the gastroenterology community."

Repligen Corporation develops new drugs for debilitating pediatric disorders including autism, immune and metabolic disorders. Repligen also manufactures and markets a set of patented products based on Protein A, which are used by the pharmaceutical industry to produce therapeutic antibodies.